[
  {
    "ts": null,
    "headline": "2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious",
    "summary": "As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is always providing investors with additional reasons to consider buying its stock.  On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious about making an investment in it.  The story of Eli Lilly has, at least recently, been a triumphant one.",
    "url": "https://finnhub.io/api/news?id=c5453154fef0f91730ffe613de7c01bfc41ec4863c7f1c4e18f6a07eb867e761",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734289500,
      "headline": "2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious",
      "id": 132003902,
      "image": "https://g.foolcdn.com/editorial/images/800833/three-investors-gather-around-laptop.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As a major pharmaceutical company that is constantly innovating and developing new treatments, Eli Lilly (NYSE: LLY) is always providing investors with additional reasons to consider buying its stock.  On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious about making an investment in it.  The story of Eli Lilly has, at least recently, been a triumphant one.",
      "url": "https://finnhub.io/api/news?id=c5453154fef0f91730ffe613de7c01bfc41ec4863c7f1c4e18f6a07eb867e761"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly Just Say \"Checkmate\" to Novo Nordisk?",
    "summary": "Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades.  In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space.  Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years.",
    "url": "https://finnhub.io/api/news?id=4ccf88ebf48a01ae97bf826c5010ef261ef9a5440cdf66dc103d77441bf17c8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734268620,
      "headline": "Did Eli Lilly Just Say \"Checkmate\" to Novo Nordisk?",
      "id": 132000158,
      "image": "https://g.foolcdn.com/editorial/images/800234/doctor-with-patient-talking.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades.  In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space.  Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years.",
      "url": "https://finnhub.io/api/news?id=4ccf88ebf48a01ae97bf826c5010ef261ef9a5440cdf66dc103d77441bf17c8a"
    }
  },
  {
    "ts": null,
    "headline": "2 Weight Loss Stocks That Are Screaming Buys in December",
    "summary": "With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines.  Zealand Pharma (OTC: ZLDP.F) is a biotech with a pipeline that's full of promising clinical-stage weight-loss programs, among other indications.  In particular, its lead anti-obesity program, a molecule called survodutide, is in phase 3 clinical trials right now, and it's unique in the sense that no weight-loss drug on the market right now utilizes the exact same mechanism of action.",
    "url": "https://finnhub.io/api/news?id=55698680000c7cf2fdecf69d277d8caab1ea8be66d3b9f2c3fe6facebf0e4e5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734262800,
      "headline": "2 Weight Loss Stocks That Are Screaming Buys in December",
      "id": 131999751,
      "image": "https://g.foolcdn.com/editorial/images/800835/3-investors-gather-around-a-laptop.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With drugs like Novo Nordisk's Wegovy becoming household names over the last couple of years, it's no surprise that there are quite a few opportunities to invest in the burgeoning market for weight-loss medicines.  Zealand Pharma (OTC: ZLDP.F) is a biotech with a pipeline that's full of promising clinical-stage weight-loss programs, among other indications.  In particular, its lead anti-obesity program, a molecule called survodutide, is in phase 3 clinical trials right now, and it's unique in the sense that no weight-loss drug on the market right now utilizes the exact same mechanism of action.",
      "url": "https://finnhub.io/api/news?id=55698680000c7cf2fdecf69d277d8caab1ea8be66d3b9f2c3fe6facebf0e4e5b"
    }
  },
  {
    "ts": null,
    "headline": "3 Unstoppable Stocks to Buy Right Now",
    "summary": "Here's why they think AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable healthcare stocks to buy right now.  David Jagielski (AstraZeneca): If you're buying a top growth stock, you often have to pay a hefty premium for it, but that isn't the case with AstraZeneca.  Despite having a wealth of products in its portfolio and a lot of growth ahead, the pharmaceutical giant trades at a fairly modest multiple of 15 times next year's estimated profits (based on analyst estimates).",
    "url": "https://finnhub.io/api/news?id=9518e0b443b7c5b63b9c8b281fdffab8fadc009fc736c4aca33de3b2c8b9ab1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734260820,
      "headline": "3 Unstoppable Stocks to Buy Right Now",
      "id": 131999003,
      "image": "https://g.foolcdn.com/editorial/images/800812/smiling-person-with-cup-looking-at-laptop.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Here's why they think AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable healthcare stocks to buy right now.  David Jagielski (AstraZeneca): If you're buying a top growth stock, you often have to pay a hefty premium for it, but that isn't the case with AstraZeneca.  Despite having a wealth of products in its portfolio and a lot of growth ahead, the pharmaceutical giant trades at a fairly modest multiple of 15 times next year's estimated profits (based on analyst estimates).",
      "url": "https://finnhub.io/api/news?id=9518e0b443b7c5b63b9c8b281fdffab8fadc009fc736c4aca33de3b2c8b9ab1e"
    }
  }
]